2 |
Sudibio S., Anton J., Handoko H., Permata T.B.M., Kodrat H., Nuryadi E., Sofyan H.R., Mulyadi R., Aman R.A., Gondhowiardjo S. |
57283461500;57328462500;57204105168;57197808751;57210639849;57197806814;57328366500;56403164500;36848942500;6508327402; |
Outcome analysis and prognostic factors in patients of glioblastoma multiforme: An indonesian single institution experience |
2021 |
Open Access Macedonian Journal of Medical Sciences |
9 |
|
|
1410 |
1416 |
|
|
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85119154241&doi=10.3889%2foamjms.2021.7502&partnerID=40&md5=9312ddc4112180679fb892c1d7cc2e79 |
Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Department of Radiation Oncology, Dr. Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia; Department of Neurology, Dr. Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia; Department of Radiology, Dr. Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia; Department of Neurosurgery, Dr. Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia |
Sudibio, S., Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia, Department of Radiation Oncology, Dr. Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia; Anton, J., Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia, Department of Radiation Oncology, Dr. Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia; Handoko, H., Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia, Department of Radiation Oncology, Dr. Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia; Permata, T.B.M., Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia, Department of Radiation Oncology, Dr. Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia; Kodrat, H., Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia, Department of Radiation Oncology, Dr. Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia; Nuryadi, E., Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia, Department of Radiation Oncology, Dr. Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia; Sofyan, H.R., Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia, Department of Neurology, Dr. Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia; Mulyadi, R., Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia, Department of Radiology, Dr. Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia; Aman, R.A., Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia, Department of Neurosurgery, Dr. Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia; Gondhowiardjo, S., Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia, Department of Radiation Oncology, Dr. Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia |
AIM: This study was done to assess the survival of patients with glioblastoma multiforme (GBM) and to identify factors that can affect patient survival. MATERIALS AND METHODS: From January 2015 to December 2019, 55 patients with histopathologically confirmed GBM and received adjuvant radiation/chemoradiation in our department were retrospectively analyzed. RESULTS: The median overall survival (OS) for entire cohort was 13 months and 1-year OS and 2-year OS rate were 52.7% and 3.6% with the mean follow-up period was 12 months. In univariate analysis, age (≤50 years vs. >50 years, p = 0.02), performance status (≥90 vs. 70–80 vs. <70, p < 0.001), radiation therapy oncology group recursive partitioning analysis (RTOG-RPA) classification (Class III vs. Class IV vs. Class V-VI, p < 0.001), parietal lobes tumor site (vs. others, p = 0.02), residual tumor volume (≤20.4 cm3 vs. >20.4 cm3, p = 0.001), and time to initiate adjuvant therapy (<4 weeks vs. 4-6 weeks vs. >6 weeks, p = 0.01) were significantly affect OS. In multivariate analysis, RTOG-RPA classification and involvement of parietal lobes were independent prognostic factors for OS. CONCLUSIONS: RTOG-RPA classification that consisted of age and performance status is an independent prognostic factor for the clinical outcome of GBM. Besides this well-known factor, we also identified the involvement of parietal lobe gives a strong negative influence on survival of GBM patients. © 2021 Sudibio Sudibio, Jellyca Anton, Handoko Handoko, Tiara Bunga Mayang Permata, Henry Kodrat, Endang Nuryadi, Henry Riyanto Sofyan, Rahmad Mulyadi, Renindra Ananda Aman, Soehartati Gondhowiardjo. |
Glioblastoma multiforme; Prognostic factors; Radiotherapy; Survival |
methylated DNA protein cysteine methyltransferase; adjuvant chemotherapy; adult; Article; basal ganglion; cancer prognosis; cancer radiotherapy; cancer size; cancer surgery; cancer survival; chemoradiotherapy; clinical outcome; cohort analysis; controlled study; corpus callosum; female; follow up; frontal lobe; glioblastoma; histopathology; human; human tissue; major clinical study; male; outcome assessment; overall survival; parietal lobe; prospective study; radiation dose; recursive partitioning; retrospective study; temporal lobe; tumor volume |
Scientific Foundation SPIROSKI |
18579655 |
|
|
Article |
Q3 |
288 |
15252 |
|
|